+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vimizim (Elosulfase Alfa) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • PDF Icon

    Report

  • 175 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 6104077
The vimizim (elosulfase alfa) market research report is one of a series of new reports that provides vimizim (elosulfase alfa) market statistics, including the vimizim (elosulfase alfa) industry global market size, regional shares, competitors with the vimizim (elosulfase alfa) market share, detailed vimizim (elosulfase alfa) market segments, market trends, and opportunities, and any further data you may need to thrive in the vimizim (elosulfase alfa) industry. This vimizim (elosulfase alfa) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing drug approvals, growing metabolic disorders, increasing hospitals, increasing investments in research and development, and rising health consciousness. Major trends in the forecast period include the integration of telemedicine for rare disease management, advancements in diagnostic tools, the integration of AI in diagnostic tools, the development of advanced drug delivery systems, and automated infusion systems.

The increasing prevalence of mucopolysaccharidosis is expected to drive the growth of the vimizim (elosulfase alfa) market in the future. Mucopolysaccharidosis is a group of rare inherited metabolic disorders caused by the body’s inability to break down complex carbohydrates called glycosaminoglycans, leading to their accumulation in cells, tissues, and organs. This rising prevalence is largely attributed to advancements in diagnostic techniques, greater awareness of the condition, and improved genetic testing. Vimizim helps treat mucopolysaccharidosis type IVA (Morquio A syndrome) by replacing the enzyme N-acetylgalactosamine-6-sulfatase, which is crucial for breaking down certain sugars, reducing the buildup of harmful substances in the body and alleviating related symptoms. According to Orphanet, the estimated prevalence of mucopolysaccharidosis ranges from 1 in 50,000 to 1 in 250,000, depending on the population. This growing prevalence is fueling the demand for vimizim.

Rising healthcare expenditure is expected to contribute to the continued growth of the vimizim market. Healthcare expenditure, which includes spending on medical treatments, hospital care, pharmaceuticals, and preventive services, is increasing due to factors such as a higher demand for advanced treatments, an aging population, and the rise in chronic diseases. This increase in healthcare expenditure is beneficial to Vimizim, as it enhances the demand for innovative healthcare solutions, improving patient outcomes and supporting healthcare providers’ investment in advanced technologies. For example, in December 2023, the Centers for Medicare & Medicaid Services reported a 4.1% increase in U.S. healthcare spending in 2022, totaling $4.5 trillion, surpassing the 3.2% growth from the previous year. The rise in healthcare expenditure is thus a key factor driving the growth of the vimizim market.

The growing demand for personalized medicine is another factor expected to propel the growth of the vimizim market. Personalized medicine tailors treatment and prevention strategies to each individual’s genetic, environmental, and lifestyle factors to improve outcomes. The increasing demand for personalized medicine is driven by advancements in genomics, heightened awareness of tailored healthcare approaches, and the growing prevalence of chronic diseases requiring individualized treatments. Vimizim, as an enzyme replacement therapy for Morquio A syndrome, fits within the personalized medicine framework by targeting the specific enzyme deficiency in each patient, thus offering a customized treatment approach. For instance, in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from the six approved in 2022, according to the Personalized Medicine Coalition. The demand for personalized medicine is therefore supporting the growth of the vimizim market.

The key company operating in the vimizim (elosulfase alfa) market is BioMarin Pharmaceutical Inc.

North America was the largest region in the vimizim (elosulfase alfa) market in 2024. The regions covered in vimizim (elosulfase alfa) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vimizim (elosulfase alfa) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Vimizim (elosulfase alfa) is a recombinant enzyme replacement therapy used to treat Morquio A syndrome (MPS IVA). It provides the deficient enzyme elosulfase alfa, which helps break down glycosaminoglycans (GAGs). Since individuals with MPS IVA cannot produce this enzyme in sufficient amounts, Vimizim offers a synthetic version to reduce the buildup of GAGs, alleviating symptoms such as joint problems, skeletal abnormalities, and respiratory issues.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indication for vimizim is mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio syndrome, as well as off-label or investigational uses. MPS IVA is a rare genetic disorder caused by a deficiency of the enzyme galactosamine-6-sulfatase, which leads to the accumulation of GAGs and results in skeletal, respiratory, and cardiovascular issues. Vimizim is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and serves various end users, including pediatric, adult, and geriatric patients.

The vimizim (elosulfase alfa) market consists of sales of vimizim injection, infusion supplies, sterile syringes and needles, saline solution, and IV pumps. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Vimizim (Elosulfase Alfa) Market Characteristics
3. Vimizim (Elosulfase Alfa) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Vimizim (Elosulfase Alfa) Market Trends And Strategies5. Vimizim (Elosulfase Alfa) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
6. Global Vimizim (Elosulfase Alfa) Growth Analysis And Strategic Analysis Framework
6.1. Global Vimizim (Elosulfase Alfa) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Vimizim (Elosulfase Alfa) Market Growth Rate Analysis
6.4. Global Vimizim (Elosulfase Alfa) Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
6.5. Global Vimizim (Elosulfase Alfa) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
6.6. Global Vimizim (Elosulfase Alfa) Total Addressable Market (TAM)
7. Global Vimizim (Elosulfase Alfa) Pricing Analysis & Forecasts
8. Vimizim (Elosulfase Alfa) Market Segmentation
8.1. Global Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Mucopolysaccharidosis Type IVA
  • Off-Label Or Investigational Uses
8.2. Global Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
8.3. Global Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Pediatric
  • Adult
  • Geriatric
9. Global Vimizim (Elosulfase Alfa) Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Vimizim (Elosulfase Alfa) Market Regional And Country Analysis
10.1. Global Vimizim (Elosulfase Alfa) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Vimizim (Elosulfase Alfa) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11. Asia-Pacific Vimizim (Elosulfase Alfa) Market
11.1. Asia-Pacific Vimizim (Elosulfase Alfa) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Vimizim (Elosulfase Alfa) Market
12.1. China Vimizim (Elosulfase Alfa) Market Overview
12.2. China Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Vimizim (Elosulfase Alfa) Market
13.1. India Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Vimizim (Elosulfase Alfa) Market
14.1. Japan Vimizim (Elosulfase Alfa) Market Overview
14.2. Japan Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Vimizim (Elosulfase Alfa) Market
15.1. Australia Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Vimizim (Elosulfase Alfa) Market
16.1. South Korea Vimizim (Elosulfase Alfa) Market Overview
16.2. South Korea Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Vimizim (Elosulfase Alfa) Market
17.1. Western Europe Vimizim (Elosulfase Alfa) Market Overview
17.2. Western Europe Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Vimizim (Elosulfase Alfa) Market
18.1. UK Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19. Germany Vimizim (Elosulfase Alfa) Market
19.1. Germany Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Vimizim (Elosulfase Alfa) Market
20.1. France Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Vimizim (Elosulfase Alfa) Market
21.1. Eastern Europe Vimizim (Elosulfase Alfa) Market Overview
21.2. Eastern Europe Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Vimizim (Elosulfase Alfa) Market
22.1. North America Vimizim (Elosulfase Alfa) Market Overview
22.2. North America Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Vimizim (Elosulfase Alfa) Market
23.1. USA Vimizim (Elosulfase Alfa) Market Overview
23.2. USA Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24. Canada Vimizim (Elosulfase Alfa) Market
24.1. Canada Vimizim (Elosulfase Alfa) Market Overview
24.2. Canada Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Vimizim (Elosulfase Alfa) Market
25.1. South America Vimizim (Elosulfase Alfa) Market Overview
25.2. South America Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Vimizim (Elosulfase Alfa) Market
26.1. Middle East Vimizim (Elosulfase Alfa) Market Overview
26.2. Middle East Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Vimizim (Elosulfase Alfa) Market
27.1. Africa Vimizim (Elosulfase Alfa) Market Overview
27.2. Africa Vimizim (Elosulfase Alfa) Market, Segmentation Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Vimizim (Elosulfase Alfa) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Vimizim (Elosulfase Alfa) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Vimizim (Elosulfase Alfa) Market Competitive Landscape And Company Profiles
28.1. Vimizim (Elosulfase Alfa) Market Competitive Landscape
28.2. Vimizim (Elosulfase Alfa) Market Company Profiles
28.2.1. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
29. Global Vimizim (Elosulfase Alfa) Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Vimizim (Elosulfase Alfa) Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vimizim (Elosulfase Alfa) Market32. Recent Developments In The Vimizim (Elosulfase Alfa) Market
33. Vimizim (Elosulfase Alfa) Market High Potential Countries, Segments and Strategies
33.1 Vimizim (Elosulfase Alfa) Market In 2029 - Countries Offering Most New Opportunities
33.2 Vimizim (Elosulfase Alfa) Market In 2029 - Segments Offering Most New Opportunities
33.3 Vimizim (Elosulfase Alfa) Market In 2029 - Growth Strategies
33.3.1 Market Trend Based Strategies
33.3.2 Competitor Strategies
34. Appendix
34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. About the Analyst
34.6. Copyright And Disclaimer

Executive Summary

Vimizim (Elosulfase Alfa) Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vimizim (elosulfase alfa) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for vimizim (elosulfase alfa) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vimizim (elosulfase alfa) market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) Clinical Indication: Mucopolysaccharidosis Type IVA; Off-Label Or Investigational Uses
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric; Adult; Geriatric

Key Companies Profiled: BioMarin Pharmaceutical Inc.

Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • BioMarin Pharmaceutical Inc.